middle.news
How Actinogen Medical’s $1.87M R&D Rebate Could Accelerate Alzheimer’s Breakthrough
5:01pm on Monday 20th of October, 2025 AEDT
•
Healthcare
Read Story
How Actinogen Medical’s $1.87M R&D Rebate Could Accelerate Alzheimer’s Breakthrough
5:01pm on Monday 20th of October, 2025 AEDT
Key Points
Advance Overseas Finding approval for FY25 overseas R&D activities
Additional $1.87 million R&D tax incentive rebate confirmed
Total FY25 R&D rebate now $7.36 million
Funding supports pivotal Alzheimer’s phase 2b/3 trial milestones in 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACW
OPEN ARTICLE